Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pemigatinib
Drug ID BADD_D02582
Description Pemigatinib is a small molecule kinase inhibitor with antitumour activity. It works by inhibiting fibroblast growth factor receptors (FGFRs), which are receptor tyrosine kinases that activate signalling pathways in tumour cells.[A193719] FGFRs gained attention as potential therapeutic targets in selected cancers, as FGFR gene alterations were observed in a wide variety of cancers including those of the urinary bladder, breast, ovary, prostate, endometrium, lung, and stomach.[A198984] Deregulated FGFR signalling pathway can lead the development of oncogenes and tumour-promoting physiological processes, such as cancer cell proliferation, enhanced angiogenesis, and evasion of cell death.[A193716] In April 2020, pemigatinib was approved by the FDA for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma in previously treated adult patients with a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangements as detected by an FDA-approved test.[L13068] Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the second most common primary hepatic malignancy. This malignancy accounts for 15% to 20% of primary hepatobiliary malignancies, which account for 13% of overall cancer-related global mortality. With increasing research on the pathogenesis of cholangiocarcinoma and potential therapeutic targets for anticancer drug treatment, recent studies show that up to 45% of patients with intrahepatic cholangiocarcinoma exhibited gene rearrangements resulting in oncogenic fibroblast growth factor 2 (FGFR2) fusion proteins.[A198963] The FDA-approved indication for pemigatinib was granted under accelerated approval based on the overall response rate and duration of response in pre-marketing clinical trials. Pemigatinib is marketed under the brand name Pemazyre, and it is available as oral tablets.[L13050]
Indications and Usage Pemigatinib is indicated for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma in previously-treated adult patients with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.[L13050]
Marketing Status approved; investigational
ATC Code L01EN02
DrugBank ID DB15102
KEGG ID D11417
MeSH ID C000705477
PubChem ID 86705695
TTD Drug ID D0O6UY
NDC Product Code 70277-503; 50881-026; 70277-501; 50881-028; 58567-108; 50881-027; 70277-502
UNII Y6BX7BL23K
Synonyms pemigatinib | 2H-Pyrrolo(3',2':5,6)pyrido(4,3-d)pyrimidin-2-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-8-(4-morpholinylmethyl)- | Pemazyre | INCB054828 | INCB-054828
Chemical Information
Molecular Formula C24H27F2N5O4
CAS Registry Number 1513857-77-6
SMILES CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Alopecia23.02.02.0010.000168%
Arthralgia15.01.02.0010.000302%
Ascites02.05.04.002; 07.07.01.001; 09.01.05.0030.000112%
Asthenia08.01.01.0010.000168%-
Calcinosis08.03.04.0020.000246%-
Cholangiocarcinoma09.04.02.009; 16.07.01.0020.000336%-
Constipation07.02.02.0010.000302%
Death08.04.01.0010.000672%
Dry skin23.03.03.0010.000112%
Dysphagia07.01.06.0030.000246%
Fatigue08.01.01.0020.000604%
Hyperphosphataemia14.04.03.0070.000604%
Nail disorder23.02.05.0020.000246%
Nausea07.01.07.0010.000302%
Pyrexia08.05.02.0030.000246%
Rash23.03.13.0010.000246%-
Rash erythematous23.03.13.0290.000246%-
Stomatitis07.05.06.0050.000168%
Thrombocytopenia01.08.01.0020.000112%-
General physical health deterioration08.01.03.0180.000112%-
Calciphylaxis14.04.01.0120.000168%-
Detachment of retinal pigment epithelium06.09.03.0110.000112%-
Decreased appetite08.01.09.028; 14.03.01.0050.000112%
Disease progression08.01.03.0380.000862%
Drug intolerance08.06.01.0130.000246%-
Cutaneous calcification23.03.03.0760.000381%-
Trichomegaly06.06.04.028; 23.02.04.0030.000381%-
The 1th Page    1    Total 1 Pages